 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...2021222324252627282930...3637» |
- || Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
My guess is an alectinib vs lorlatinib trial wouldn’t have gone so well for them, totally agree (Twitter) - Nov 19, 2020
- ||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
That said all the 2L ALK TKI (alectinib, brigatinib) have excellent CNS activity, depth of CNS responses (icCR) varies but influenced by XRT (Twitter) - Nov 19, 2020
- |||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
The authors of this trial knew very early in accrual that alectinib was superior to crizotinib, but, of course, they continued enrolling to the inferior control arm The control arms of RCTs in cancer medicine needs massive ethical investigation. It is really bad. (Twitter) - Nov 19, 2020
- || Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
The life cycle of targeted drugs keeps getting shorter. Crizotinib approved 2011; alectinib 2017; lorlatinib data here. https://t.co/VU6OarB5nC (Twitter) - Nov 19, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: Ideally need to have a randomised trial comparing upfront alectinib (followed by lorlatinib on progression) vs. upfront lorlatinib. Difficult to guess if and when that would be done (Twitter) - Nov 18, 2020
- |||| New P2 trial, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MyTACTIC: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (clinicaltrials.gov) - Nov 17, 2020
P2, N=200, Not yet recruiting, Sponsor: Genentech, Inc.
- || Lorbrena (lorlatinib) / Pfizer
Clinical, Retrospective data, Journal: Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. (Pubmed Central) - Nov 14, 2020
Lorlatinib treatment was well tolerated. Later-line lorlatinib treatment can induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer.
- | Alecensa (alectinib) / Roche
Journal: Alectinib-Associated Perforated Duodenal Ulcer. (Pubmed Central) - Nov 14, 2020
Later-line lorlatinib treatment can induce sustained responses in patients with advanced ALK- and ROS1-positive lung cancer. No abstract available
- |||| Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Pan tumor, Immuno-oncology: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (clinicaltrials.gov) - Nov 12, 2020
P2, N=650, Recruiting, Sponsor: Hoffmann-La Roche
No abstract available Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO Biomarker: New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. (Pubmed Central) - Nov 11, 2020
Not yet recruiting --> Recruiting Challenges in NSCLC treatment include resistance to 3rd generation TKIs, the high cost of ALK inhibitors, and the need for further research on new drugs.
- | Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) - Nov 9, 2020
P2, N=384, Recruiting, Sponsor: Fondazione per la Medicina Personalizzata
Challenges in NSCLC treatment include resistance to 3rd generation TKIs, the high cost of ALK inhibitors, and the need for further research on new drugs. Not yet recruiting --> Recruiting
- || Xalkori (crizotinib) / Pfizer, Retevmo (selpercatinib) / Eli Lilly, Alecensa (alectinib) / Roche
Clinical, Journal: A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. (Pubmed Central) - Nov 7, 2020
This novel fusion with CCDC6 has not previously been reported in other human cancers. Given the dramatic response to ALK inhibition in this case, identifying patients with ALK fusion MTC has important therapeutic implications.
- |||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: One of the novel ALK mutations noted here was #ALK L1196Q which we had actually previously noted in a patient after 2nd line alectinib and in our case (led by Dr. Hira Latif, @UMGCCC), a durable response was garnered with brigatinib (ongoing at 18 months) https://t.co/r5OPNJW0nL (Twitter) - Nov 6, 2020
- | Journal: Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. (Pubmed Central) - Nov 2, 2020
In conclusion, anti-EGF VacAbs significantly increased the antitumor activity of TKIs in ALK and RET-positive cell lines. Clinical trials of an EGF vaccine in combination with ALK and RET TKIs are warranted.
- Alecensa (alectinib) / Roche
[VIRTUAL] Reduced Dose of Alectinib Achieved Rapid and Remarkable Disease Control in a Super-aged Advanced Lung Adenocarcinoma Patient Harboring EML-ALK Fusion () - Oct 31, 2020 - Abstract #CTSChina2020CTS-China_855;
- | Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
Journal: Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate? (Pubmed Central) - Oct 28, 2020
Clinical trials of an EGF vaccine in combination with ALK and RET TKIs are warranted. No abstract available
- | Journal: Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma. (Pubmed Central) - Oct 25, 2020
HSN608 inhibited the growth of CCDC6-RET driven LC-2/ad cell line with IC50 of ~3 nM. Under similar conditions, BLU667 and vandetanib (two drugs being evaluated against RET-driven cancers in the clinic) inhibited the growth of LC-2/ad with IC50 values of ~10 and 328 nM respectively.
- [VIRTUAL] Comparative efficacy of first-line ALK-inhibitors in ALK+ lung cancer brain metastases: A network meta-analysis () - Oct 24, 2020 - Abstract #SNO2020SNO_515;
This network meta-analysis is the first to compare and rank approved ALKIs used in treating metastatic ALK+ lung cancer. It indicates that BRG, CER, and ALC are better therapeutic options for patients with ALK-naive ALK+ lung cancer brain metastases when compared to CRZ.
- || Alecensa (alectinib) / Roche
Clinical, Journal: A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors. (Pubmed Central) - Oct 22, 2020
She recovered a complete visus and actually she still continue therapy with alectinib. The patient had a complete recovery of visus in addiction to a long response on treatment.
- || Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 19, 2020
P2a, N=658, Active, not recruiting, Sponsor: Genentech, Inc.
The patient had a complete recovery of visus in addiction to a long response on treatment. Trial primary completion date: Sep 2020 --> Mar 2021
- ||||| New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Pan tumor, Immuno-oncology: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (clinicaltrials.gov) - Oct 19, 2020
P2, N=650, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) - Oct 18, 2020
P2, N=384, Not yet recruiting, Sponsor: Fondazione per la Medicina Personalizzata
- || Review, Journal: Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer. (Pubmed Central) - Oct 15, 2020
The central nervous system (CNS) activity of alectinib and brigatinib has allowed for treatment of CNS metastases with TKI therapy. Once resistance inevitably develops, newer therapies such as lorlatinib can be considered.
- |||| Alecensa (alectinib) / Roche
Enrollment closed: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (clinicaltrials.gov) - Oct 13, 2020
P3, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Once resistance inevitably develops, newer therapies such as lorlatinib can be considered. Recruiting --> Active, not recruiting
- paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] DOUBLE PRIMARY MALIGNANCY: AN UPCOMING TREND () - Oct 12, 2020 - Abstract #CHEST2020CHEST_1975;
Since, she has been treated with neoadjuvant chemotherapy (CTX) for breast primary with Adriamycin, Cyclophosphamide, Taxol regimen (AC-T) and Alectinib CTX for lung primary. With increased incidence of MPMN, this case report emphasizes the importance of possibility of multiple primaries to be taken into consideration, by treating physician.
- || Alecensa (alectinib) / Roche
Clinical, Journal: Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib. (Pubmed Central) - Oct 7, 2020
With increased incidence of MPMN, this case report emphasizes the importance of possibility of multiple primaries to be taken into consideration, by treating physician. No abstract available
- || Alecensa (alectinib) / Roche
Or "Seems to be as good as what we already have with alectinib, but you also give up effective subsequent therapy." (Twitter) - Oct 6, 2020
- || Alecensa (alectinib) / Roche
Clinical, P2 data, Journal: Alectinib for relapsed or refractory ALK-positive anaplastic large cell lymphoma: an open label phase 2 trial. (Pubmed Central) - Oct 4, 2020
Alectinib showed favorable clinical activity and was well tolerated in patients with ALK-positive ALCL who had progressed on standard chemotherapy. Based on the results of current study, Ministry of Health, Labour and Welfare in Japan has approved alectinib for the treatment of recurrent or refractory ALK-positive ALCL in February 2020.
- Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Alecensa (alectinib) / Roche, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
[VIRTUAL] Cost Containment in the Netherlands- Lock IT DOWN () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1867;
Since the Netherlands introduced the lock system, the policy is adding scrutiny on drugs with high budget impacts that exceed >€40 million a year or >€10 million a year and treatment costs per patient >€50,000. ZIN started to extract mandatory and confidential discounts, at the trade-off of delayed broad patient access for the duration of the lock.
- Lorbrena (lorlatinib) / Pfizer
[VIRTUAL] An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1744;
RESULTS : Treatment with lorlatinib allowed for a gain of 1.87 life years (LYs) or 1.40 quality-adjusted life years (QALYs) in patients whose disease progressed after alectinib or ceritinib and a gain of 1.57 LYs or 1.04 QALYs in patients whose disease progressed after crizotinib and another ALK TKI. Sensitivity analyses showed that the model was robust to parameter variation, except for the extrapolations of OS and ToT for lorlatinib.CONCLUSIONS : Lorlatinib results in increased life expectancy and quality-adjusted life expectancy compared with PBC in previously treated adult patients with ALK-positive NSCLC in the Portuguese setting.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] Cost-Effectiveness Analysis of Alectinib Compared to Crizotinib for the Treatment of Naïve Patients with ALK-Positive NON-SMALL Cell LUNG Cancer (NSCLC) in Colombia () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1072;
The incremental QALY was 0.60 in favor of alectinib and the ICER is a cost-saving alternative(-US$45,564.48/QALY). CONCLUSIONS : Alectinib, as a first-line treatment of ALK+ NSCLC compared to crizotinib, is a cost-saving alternative in the Colombian setting.
- Alecensa (alectinib) / Roche
[VIRTUAL] Effectiveness of Alectinib in a Real-World US Cohort () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_912;
CONCLUSIONS : Absolute survival in this real-world cohort of ALK+ mNSCLC patients treated with alectinib was similar to that demonstrated in the ALEX clinical trial. These results suggest the benefit of alectinib demonstrated in clinical trials is being realized in real-world populations.
- Alecensa (alectinib) / Roche
[VIRTUAL] Health-Related Quality of Life (HRQOL) of ALK-Rearranged NON-SMALL CELL LUNG Cancer (NSCLC) Patients Treated in Second LINE with Alectinib () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_618;
ALK-rearranged NSCLC patients have high symptom burden and severe morbidity, HRQoL is therefore important to take into consideration. In the ATALK study, QLQ-C30 global health status and functional scores increased during the study while symptoms score decreased (except for constipation).
- || Alecensa (alectinib) / Roche
Clinical, Journal: Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma. (Pubmed Central) - Oct 3, 2020
The patient's anemia and hemolysis gradually improved after discontinuation of alectinib, leading to a diagnosis of alectinib-induced IHA, presented here as the first case encountered in a patient with lung adenocarcinoma. Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA.
- |||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
#ThoracicOnc2020Virtual Closing thoughts on alectinib vs lorlatinib by @oncoOuLungCA - is it time to pass the torch? #LCSM (Twitter) - Oct 2, 2020
- |||| Alecensa (alectinib) / Roche
Head-to-Head: Certainly promising data but we would like to have head to head with Alectinib. Sequencing it’s still a question in ALKi , as well combinations with other agents. @christine_lovly @ALKLungCancer @alk_fusion (Twitter) - Oct 2, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Agree that beating crizotinib in 2020 is damning with faint praise. That's not a remotely current comparator. We also need to weigh loss of availability of lorlatinib for treatment upon progression, & a potentially challenging toxicity profile w/lorlatinib vs. alectinib. #LCSM (Twitter) - Oct 1, 2020
- |||| Tagrisso (osimertinib) / AstraZeneca, sotorasib (AMG 510) / Amgen, Alecensa (alectinib) / Roche
Clinical: IMO, data on sotorasib (aka AMG 510) were a "glass half empty vs. half full" story. Many colleagues express disappointment. Its response rate of 32% isn't in same league as Tagrisso or Alecensa, but c'mon -- it's KRAS, & these are previously treated pts. Not a bad 1st step. #LCSM (Twitter) - Oct 1, 2020
- |||||| Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: long survival in Alk + NSCLC patients treated with brigatinib after progression of alectinib and crizotinib, future oncology 2020 @AndresFCardonaZ @DrFbarron @Deibitforce @LuisLara_M (Twitter) - Sep 28, 2020
- |||| Enrollment open, Trial initiation date, PD(L)-1 Biomarker: ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (clinicaltrials.gov) - Sep 24, 2020
P2, N=300, Recruiting, Sponsor: Ulrik Lassen
Furthermore, we discuss the importance of correlating clinical laboratory findings in DIIHA. Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Aug 2020
- ||||| Alecensa (alectinib) / Roche
Clinical: Photobombed by #elmo chair in his office @VamsiVelcheti covers other targets in #lungcancer #lcsm high population of those with brain mets @nyulangone chair @DrSteveMartin @MontefioreNYC alectinib had mostly hepatic toxicity predominantly (Twitter) - Sep 24, 2020
- ||| Alecensa (alectinib) / Roche
Clinical: It’s great that the field is moving forward so quickly. At the time CROWN opened, the Alectinib was not approved for first line and the ALEX study hadn’t even been presented. (Twitter) - Sep 23, 2020
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Journal: ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. (Pubmed Central) - Sep 23, 2020
Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Aug 2020 There is no clear evidence of sensitization to radiation by treating EML4-ALK mutated cells with ALK inhibitors.
- || Alunbrig (brigatinib) / Takeda
Clinical, Journal, Real-World Evidence: Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. (Pubmed Central) - Sep 21, 2020
Six patients had received alectinib as monotherapy, second-line, or third line before brigatinib; of these, four experienced partial responses and two progressed responses. Brigatinib treatment was well tolerated.
- || Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Considering how dismal and well known criz pfs data is, this all means nothing and is nothing to crow about and doesn’t advance science. 3 arms or more w alectinib and brigatinib obviously academic study that should be done (Twitter) - Sep 21, 2020
- || Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Honestly don't understand how a doctor could recruit for this trial. They would never allow their loved one to take crizotinib over alectinib after the results on the left, yet, a few days later they are willing to permit randomization to it to help a competitor drug/ company? (Twitter) - Sep 21, 2020
- || Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Tried and true alectinib wins out. Am curious as more get experience with managing lipids and neurotox of lorlatinib in 2L whether comfort to use lorlatinib in 1L may increase if one feels their best option (Twitter) - Sep 20, 2020
- ||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
P3 data: It’s great that so many phase 3’s are complete, and a speaks to the fact that at least one phase 3 in the post alectinib/brigatinib setting could be done, and at least one phase 3 with other driver mutations such as Metex14 and Ret (libretto-431) should be feasible. (Twitter) - Sep 20, 2020
- |||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
FDA event: At time of 1L alectinib FDA approval in 11/2017 with median 18m f/u, 8% deaths with alectinib, 7% in crizotinib. OS improved in ALEX now, but not seen in ALEX-J even with median 42m f/u. I want to know 1L loralatinib v. alectinib line, too. Just explaining why it didn't happen. (Twitter) - Sep 20, 2020
- ||| Alecensa (alectinib) / Roche
Clinical: After alectinib became first line approved and standard of care, the study should have been stopped and amended to allow patients in standard arm to get alectinib. (Twitter) - Sep 20, 2020